Pelthos Therapeutics Inc.(PTHS)Stock Analysis

PTHS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Pelthos Therapeutics Inc. (PTHS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTHS at 25.4/100 on a 32-signal composite quality model, placing it at rank #2,543 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (9.7) and institutional flow (22.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Pelthos Therapeutics Inc. reports quarterly revenue of $10.9M, net income of $-10.2M, free cash flow of $-13.3M. Top institutional holders of PTHS by reported 13-F value include Murchinson Ltd., Ikarian Capital,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PTHS trades on the NYSE exchange and files with the SEC under CIK 1919246. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTHS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pelthos Therapeutics Inc. directly from SEC EDGAR.